MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-03-2026
Teva Pharmaceutical Industries Limited General and Administrative Expenses 2011-2026 | TEVA
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Teva Pharmaceutical Industries Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 1.16 B | 1.16 B | 1.18 B | 1.1 B | 1.17 B | 1.19 B | 1.3 B | 1.33 B | 1.24 B | 1.24 B | 1.22 B | 1.24 B | 1.24 B | 932 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.33 B | 932 M | 1.2 B |
Quarterly General and Administrative Expenses Teva Pharmaceutical Industries Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 317 M | 305 M | 297 M | 298 M | 283 M | 278 M | 268 M | 307 M | 296 M | - | 283 M | 313 M | 296 M | - | 291 M | 242 M | 290 M | - | 279 M | 264 M | 304 M | - | 285 M | 296 M | 292 M | - | 309 M | 316 M | 329 M | - | 372 M | 363 M | 366 M | - | 310 M | 311 M | 304 M | - | 316 M | 325 M | 307 M | - | 293 M | 302 M | 302 M | - | 297 M | 319 M | 307 M | - | 292 M | 316 M | 312 M | - | 112 M | 284 M | 221 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 372 M | 112 M | 297 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
286 M | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 4.48 | - | $ 736 M |  Britain |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
80.9 M | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
101 M | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
43.8 M | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
5.94 M | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
6.21 M | $ 2.32 | - | $ 1.03 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
63.1 M | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
15.2 M | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
14.2 M | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
14 M | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
191 M | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
73.5 M | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
29.8 M | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
18.2 M | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
16.2 M | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
32.8 M | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
105 M | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
890 K | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
9.28 M | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
4.89 M | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
10.8 M | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
46.5 M | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | USA |